To confirm that treatment with BI 2536 and BI 6727 inhibits activation of Plk1 in MKN45 CSC-like cells and cancer cells, we measured the phosphorylation of Myelin transcription factor 1 (Myt1), a Plk1 substrate. The gene discussed is PLK1; the disease is cancer.